Progress towards an HIV cure
How much longer have I got?
People who aren't taking HIV treatment are a major source of transmitted resistance in Swiss gay men
Systematic review and meta-analysis shows equivalence of 3TC and FTC
HIV may be becoming less fit as it adapts to the immune system
Once-daily raltegravir effective as maintenance therapy
HIV rebound linked to higher baseline level, slower suppression and low-level viraemia
Dolutegravir matches or surpasses other regimens for first-line HIV treatment
